Technical Momentum Gains Traction
Strides Pharma Science Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its technical trend upgrade from mildly bullish to bullish as of mid-September 2026. The stock closed at ₹1,188.55 on 17 Sep 2026, up 3.13% from the previous close of ₹1,152.50, with intraday highs touching ₹1,192.00. This price action reflects growing buying interest and a strengthening momentum backdrop.
The Moving Average Convergence Divergence (MACD) indicator, a key momentum oscillator, is bullish on both weekly and monthly charts, signalling sustained upward momentum. Complementing this, Bollinger Bands also show bullish patterns on weekly and monthly timeframes, indicating that price volatility is expanding in favour of the bulls. Daily moving averages further reinforce this positive trend, with the stock price comfortably above key averages, suggesting strong short-term support.
However, not all indicators are uniformly positive. The Know Sure Thing (KST) oscillator remains mildly bearish on weekly and monthly charts, hinting at some underlying caution among traders. Similarly, Dow Theory analysis shows no clear trend on the weekly scale and a mildly bearish stance monthly, suggesting that while momentum is building, some longer-term trend uncertainty persists. The Relative Strength Index (RSI) remains neutral with no clear signal on weekly or monthly charts, indicating the stock is neither overbought nor oversold at present.
Price Performance Outpaces Benchmarks
Strides Pharma’s recent price momentum is further validated by its impressive returns relative to the broader market. Over the past month, the stock has surged 22.78%, vastly outperforming the Sensex’s decline of 4.71%. Year-to-date, Strides Pharma has delivered a robust 31.72% gain, while the Sensex has fallen 12.77%. Even over longer horizons, the stock’s performance is remarkable: a 35.39% return over one year compared to the Sensex’s negative 9.76%, and a staggering 425.88% gain over three years versus the Sensex’s modest 9.58%.
This outperformance underscores the company’s resilience and growth potential within the pharmaceuticals and biotechnology sector, which has been subject to volatility but remains a key area of investor focus due to ongoing innovation and demand for healthcare solutions.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
On-Balance Volume and Trend Signals
The On-Balance Volume (OBV) indicator, which measures buying and selling pressure, shows a bullish trend on the monthly chart, signalling accumulation by investors over the longer term. However, the weekly OBV remains neutral, suggesting that short-term volume trends are yet to decisively confirm the bullish momentum.
Despite some mixed signals from KST and Dow Theory, the overall technical picture leans towards a strengthening bullish trend. The stock’s proximity to its 52-week high of ₹1,231.45, compared to a low of ₹769.60, highlights the significant upside potential that remains. The current price level near ₹1,188.55 suggests the stock is trading at a premium but still within a range that technical indicators deem sustainable.
Mojo Score and Rating Revision
Reflecting these technical developments, the company’s Mojo Score stands at 64.0, with a revised Mojo Grade of Hold as of 15 Sep 2026, downgraded from a previous Buy rating. This adjustment indicates a more cautious stance by analysts, balancing the bullish technical momentum against some lingering uncertainties in trend confirmation and sector volatility.
Strides Pharma’s small-cap status adds an element of risk and reward, as smaller companies often exhibit greater price swings but also offer higher growth potential. Investors should weigh these factors carefully when considering exposure to this stock.
Holding Strides Pharma Science Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
For investors analysing Strides Pharma Science Ltd, the recent technical upgrades signal a positive shift in price momentum, supported by bullish MACD and Bollinger Bands on multiple timeframes and strong daily moving averages. The stock’s outperformance relative to the Sensex over various periods further bolsters confidence in its growth trajectory.
Nonetheless, caution is warranted given the mixed signals from KST and Dow Theory, as well as the neutral RSI readings. These suggest that while momentum is building, the stock may face intermittent volatility or consolidation phases before a sustained uptrend is firmly established.
Given the company’s small-cap classification and the sector’s inherent risks, investors should consider a balanced approach, monitoring technical indicators closely and staying alert to broader market developments in pharmaceuticals and biotechnology.
Overall, Strides Pharma Science Ltd presents a compelling case for investors seeking exposure to a fundamentally sound and technically improving stock within a dynamic sector, with the potential for attractive returns if bullish momentum continues to build.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
